<DOC>
	<DOCNO>NCT01584921</DOCNO>
	<brief_summary>Erythropoietin ( EPO ) glycoprotein produce mainly kidney . After release bloodstream EPO bind receptor predominantly locate within bone marrow erythropoiesis stimulate . Recently , show recombinant human EPO ( rHuEPO ) down-regulates circulating level renin aldosterone . Concomitant clearance study reveal decrease proximal tubular reabsorption sodium water fall glomerular filtration rate ( GFR ) . These result first time demonstrate link EPO renal function : By inhibit proximal tubular reabsorption , turn result rapid decline GFR renin/aldosterone level , EPO may directly reduce major oxygen consume factor kidney . The expected result increase oxygen tension environment renal EPO produce cell , way initiate appropriate signal down-regulation endogenous EPO synthesis circulating level EPO high . The aim project test hypothesis investigate renal effect rHuEPO human . In double-blinded manner healthy subject test placebo , low-dose rHuEPO two week , high-dose rHuEPO three day . Accurate sodium balance study conduct together renal clearance study measurements renal plasma flow ( 131I-Hippuran clearance renal venous sample ) , GFR ( 51Cr-EDTA clearance ) segmentel tubular handle sodium water ( lithium clearance ) . EPO sole haematopoietic growth factor mainly produce kidney project provide new information basic physiological issue regard association renal function regulation EPO synthesis .</brief_summary>
	<brief_title>Renal Effects Erythropoietin Humans</brief_title>
	<detailed_description>The haematopoietic effect EPO rHuEPO know five decade still exact mechanism regulation EPO synthesis kidney remain unclear . Recently , confirm previous observation rHuEPO normal subject produce arterial hypertension reduction plasma volume . Moreover , study delineate time course change : rHuEPO promptly , change hematocrit , blood volume blood pressure detect , cause down-regulation renin-aldosterone system , proximal tubular reabsorption GFR . The effect rHuEPO arterial blood pressure demonstrate occur independent haematopoietic effect subsequent effect blood viscosity . Recently , report also short-time administration high dos rHuEPO ( 30,000 IU/day three day ) increase arterial blood pressure blood pressure response exercise similar extent prolong , low-dose rHuEPO three month . The exact mechanism remain unclear , may involve rHuEPO induced release endothelin inhibition eNOS mediate production NO . The early rHuEPO induce reduction renin aldosterone cause change plasma blood volume . A fall intravascular volume normally lead opposite effect due decrease NaCl load macula densa increase sympathetic stimulation juxtaglomerular apparatus . The link administration rHuEPO renin-angiotensinaldosterone system interesting production endogenous EPO regulate system . Administration angiotensin II human stimulate EPO synthesis , conversely , inhibitor angiotensin convert enzyme angiotensin II receptor decrease plasma concentration endogenous EPO . In patient type-1 diabetes , inherent high activity basal renin-angiotensin system ( part govern genetic factor ) associate high level EPO compare patient low activity basal renin-angiotensin system . Our result suggest rHuEPO may activate opposite pathway down-regulate activity renin-angiotensin-aldosterone system independent change red blood cell mass , blood volume blood pressure . Our renal clearance data suggest rHuEPO-induced inhibition renin-aldosterone system associate reduction absolute proximal tubular reabsorption fluid fall GFR . Changes end-proximal delivery tubular fluid macula densa produce inverse change renin release thus suppression plasma renin level may secondary direct effect rHuEPO proximal tubular reabsorption . In addition , decrease proximal tubular reabsorption activate tubuloglomerular feedback mechanism cause parallel decrease GFR . The exact molecular mechanism rHuEPO 's effect proximal tubule remain unknown may involve inhanced release renal endothelin-1 low dos attenuate sodium reabsorption proximal tubule . Tubular reabsorption sodium main oxygen consume process kidney around 70 % filter load reabsorb proximal tubule . By inhibit proximal tubular reabsorption , turn result rapid decline GFR renin/aldosterone level , rHuEPO may directly reduce major oxygen consume factor kidney , reduce filter load , decrease angiotensin II aldosterone dependent reabsorption distal nephron segment . Thus , suggest renal effect rHuEPO may part feedback system serve down-regulate endogenous renal synthesis EPO presence high level circulate EPO . In support feedback system , evidence exists indicate prolonged administration rHuEPO result suppression urinary excretion endogenous EPO , also renal effect rHuEPO fit well hypothesis advance Donnelly , argue kidney operate 'critmeter ' regulate EPO synthesis body haematocrit metabolic signal renal tissue oxygen pressure . It suggest reduction plasma volume induce rHuEPO may cause hyporeninemic hypoaldosteronism lead natriuresis . In previous study perform actual sodium balance study . However , renal sodium loss necessary account observe decrease plasma volume small , possible net effect rHuEPO cause negative sodium balance entire 28 day treatment period . Hypotheses 1. rHuEPO decrease renal proximal tubular reabsorption , concentration renin aldosterone , GFR , overall renal perfusion . 2 . In subject sodium-fixed diet , rHuEPO increase sodium excretion cause negative sodium balance . 3. rHuEPO decrease renal oxygen consumption augment oxygen tension EPOproducing , interstitiel fibroblast-like cell juxtamedullary region . 4. rHuEPO decrease renal synthesis secretion endogenous EPO . 5 . Blockade specific endothelin antagonist ( Bosantan ) inhibit renal effect rHuEPO . Research plan methods The project include normal subject rHuEPO administer accord previous protocol use group . In separate series subject give either 1 ) placebo , 2 ) rHuEPO ( 5,000 IU ) every second day two week , 3 ) rHuEPO ( 30,000 IU/day ) three day . Measurements obtain day 4 , 11 , 28 . The trial plan conduct double-blinded , cross-over design subject randomise three consecutive trial period either placebo , low-dose rHuEPO high-dose rHuEPO separate least six week .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male Age 2040 year Non smoker min . year BP 140/90 No medicine use BMI 25 Participation medical trail Allergi towards Erythropoietin Malignity diseases Epilepsy Staying 1500 meter within last 3 month Polycythemia Elite athlete Haematocrit 55 %</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Glomerular filtration rate</keyword>
	<keyword>Tubular reabsorption</keyword>
	<keyword>Renal function</keyword>
	<keyword>Renal perfusion</keyword>
</DOC>